Investing in employees’ wellbeing and empowering them is directly proportional to their productivity and success. It is a well-acknowledged fact that human resources are the…
News Category: Media
Cell line platform reduces timelines by 33%, says Aragen
Aragen Life Sciences has launched its RapTr 2022 cell line development platform, which it says offers reduced timelines and delivers increased titres. Contract development manufacturing…
China’s challenge in the drug services field
WuXi AppTec has had a great year so far. The Shanghai-based company, perhaps the world’s largest contract research and manufacturing firm serving the drug industry,…
Automation accelerators in drug discovery and development
Digital transformation is paving way for improved efficiency and efficacy in pharmaceutical industry. With changing global business environment and shortage of resource dexterities —automation and…
Aragen sets it sights on biologics manufacturing with India facility
CDMO Aragen Life Sciences plans to build a biologics manufacturing plant in Bangalore, India, the firm told BioProcess Insider at CPhI Frankfurt. Chief commercial officer Ramesh Subramanian…
Predicting Pharma’s Future
Predictive analysis is a tricky business–it’s difficult to find experts who can not only thoroughly document trends of the past year, but also understand the…
CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences
In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, in each of the different categories,…
Aragen continues to ride CDMO growth wave as CEO honoured at CPHI Awards
Aragen’s good year continues as CEO Manni Kantipudi took home the ‘CEO of the Year’ Award at the CPHI 2022. “Outstanding performance with sustained growth…
Best practices & strategies for biotherapeutics production using a stable scale-up process
Biopharmaceutical medicinal products, or biologics, are already an integral component of therapeutic strategies to treat various human diseases.1 Biologics, which mostly consist of therapeutic recombinant…
Long-acting injectables for biologics: Current landscape and future perspective
Biologics are incredibly powerful and targeted. For these reasons, pharmaceutical companies have invested a lot of time and money over the past 20 years developing…
